US2019022112A1PendingUtilityA1

Controlled release and taste masking oral pharmaceutical compositions

72
Assignee: COSMO TECH LIMITEDPriority: Jun 14, 1999Filed: Sep 24, 2018Published: Jan 24, 2019
Est. expiryJun 14, 2019(expired)· nominal 20-yr term from priority
Inventors:Roberto VillaMassimo PedraniMauro AjaniLorenzo Fossati
A61P 9/00A61P 9/12A61P 43/00A61P 25/22A61P 25/18A61P 25/16A61P 29/00A61P 31/04A61P 25/00A61P 25/04A61P 3/10A61P 11/08A61P 1/04A61P 11/14A61P 1/00A61K 9/2866A61K 9/1617A61K 9/2846A61K 9/1652A61K 9/282A61K 9/209A61K 9/2806A61K 31/58A61K 9/2027A61K 9/2009A61K 9/28A61K 9/2054A61K 9/2077A61K 9/0053A61K 9/2813A61K 9/2018A61K 9/2013
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . A controlled release oral pharmaceutical composition consisting essentially of:
 (1) a tableted core consisting of a dispersion of ingredients, said ingredients comprising:
 a) budesonide in an amount to treat intestinal inflammation; 
 b) magnesium stearate, stearic acid, or a mixture thereof; 
 c) hydroxyalkyl cellulose; and 
 d) optionally starch or a starch derivative; and 
   (2) a coating on said tableted core, said coating consisting essentially of a gastro-resistant film.   
     
     
         4 . The controlled release oral pharmaceutical composition according to  claim 3 , wherein said ingredients further comprise lactose. 
     
     
         5 . The controlled release oral pharmaceutical composition according to  claim 3 , wherein said ingredients comprise magnesium stearate. 
     
     
         6 . The controlled release oral pharmaceutical composition according to  claim 3 , wherein said hydroxyalkyl cellulose is hydroxypropyl methylcellulose. 
     
     
         7 . The controlled release oral pharmaceutical composition according to  claim 3 , wherein said ingredients comprise starch. 
     
     
         8 . The controlled release oral pharmaceutical composition according to  claim 7 , wherein said ingredients comprise magnesium stearate. 
     
     
         9 . The controlled release oral pharmaceutical composition according to  claim 8 , wherein said ingredients further comprise lactose. 
     
     
         10 . The controlled release oral pharmaceutical composition according to  claim 7 , wherein said hydroxyalkyl cellulose is hydroxypropyl methylcellulose. 
     
     
         11 . The controlled release oral pharmaceutical composition according to  claim 3 , wherein said ingredients comprise a starch derivative and magnesium stearate. 
     
     
         12 . The controlled release oral pharmaceutical composition according to  claim 11 , wherein said hydroxyalkyl cellulose is hydroxypropyl methylcellulose. 
     
     
         13 . The controlled release oral pharmaceutical composition according to  claim 3 , wherein said ingredients comprise a starch derivative and magnesium stearate and further comprise lactose, lecithin, and microcrystalline cellulose. 
     
     
         14 . The controlled release oral pharmaceutical composition according to  claim 13 , wherein said hydroxyalkyl cellulose is hydroxypropyl methylcellulose. 
     
     
         15 . The controlled release oral pharmaceutical composition according to  claim 3 , wherein said gastro-resistant film comprises methacrylic acid polymer. 
     
     
         16 . The controlled release oral pharmaceutical composition according to  claim 4 , wherein said gastro-resistant film comprises methacrylic acid polymer. 
     
     
         17 . The controlled release oral pharmaceutical composition according to  claim 5 , wherein said gastro-resistant film comprises methacrylic acid polymer. 
     
     
         18 . The controlled release oral pharmaceutical composition according to  claim 6 , wherein said gastro-resistant film comprises methacrylic acid polymer. 
     
     
         19 . The controlled release oral pharmaceutical composition according to  claim 7 , wherein said gastro-resistant film comprises methacrylic acid polymer. 
     
     
         20 . The controlled release oral pharmaceutical composition according to  claim 8 , wherein said gastro-resistant film comprises methacrylic acid polymer. 
     
     
         21 . The controlled release oral pharmaceutical composition according to  claim 9 , wherein said gastro-resistant film comprises methacrylic acid polymer. 
     
     
         22 . The controlled release oral pharmaceutical composition according to  claim 10 , wherein said gastro-resistant film comprises methacrylic acid polymer. 
     
     
         23 . The controlled release oral pharmaceutical composition according to  claim 11 , wherein said gastro-resistant film comprises methacrylic acid polymer. 
     
     
         24 . The controlled release oral pharmaceutical composition according to  claim 12 , wherein said gastro-resistant film comprises methacrylic acid polymer. 
     
     
         25 . The controlled release oral pharmaceutical composition according to  claim 13 , wherein said gastro-resistant film comprises methacrylic acid polymer. 
     
     
         26 . The controlled release oral pharmaceutical composition according to  claim 14 , wherein said gastro-resistant film comprises methacrylic acid polymer. 
     
     
         27 . A method for treating intestinal inflammatory disease in a patient, comprising administering to the patient the controlled release oral pharmaceutical composition according to  claim 3 . 
     
     
         28 . A method for treating intestinal inflammatory disease in a patient, comprising administering to the patient the controlled release oral pharmaceutical composition according to  claim 4 . 
     
     
         29 . A method for treating intestinal inflammatory disease in a patient, comprising administering to the patient the controlled release oral pharmaceutical composition according to  claim 5 . 
     
     
         30 . A method for treating intestinal inflammatory disease in a patient, comprising administering to the patient the controlled release oral pharmaceutical composition according to  claim 7 . 
     
     
         31 . A method for treating intestinal inflammatory disease in a patient, comprising administering to the patient the controlled release oral pharmaceutical composition according to  claim 11 . 
     
     
         32 . A method for treating intestinal inflammatory disease in a patient, comprising administering to the patient the controlled release oral pharmaceutical composition according to  claim 15 .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.